Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,445 Cr
Revenue (TTM)
₹589 Cr
Net Profit (TTM)
₹102 Cr
ROE
11.8 %
ROCE
11.9 %
P/E Ratio
33.9
P/B Ratio
4.1
Industry P/E
33.39
EV/EBITDA
19.1
Div. Yield
0 %
Debt to Equity
0.4
Book Value
₹184
EPS
₹22.1
Face value
10
Shares outstanding
46,053,588
CFO
₹--
EBITDA
₹--
Net Profit
₹--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Senores Pharmaceuticals
| -7.0 | -6.9 | -4.3 | 23.1 | -- | -- | -- |
|
BSE Healthcare
| -3.1 | -2.9 | -3.1 | 4.0 | 25.0 | 15.7 | 10.7 |
|
Company
|
2025
|
|---|---|
|
Senores Pharmaceuticals
| 43.9 |
|
BSE Small Cap
| -6.6 |
|
BSE Healthcare
| -3.3 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
765.1 | 3,444.8 | 588.5 | 102.9 | 22.1 | 12.7 | 33.9 | 4.1 |
| 349.5 | 3,112.8 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.4 | 2.1 | |
| 924.0 | 11,539.7 | 2,512.3 | 543.7 | 28.3 | 19.3 | 21.2 | 3.6 | |
| 368.9 | 6,657.6 | 1,053.1 | 293.6 | 32.3 | 24.6 | 22.7 | 5.1 | |
| 1,131.2 | 11,940.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,510.4 | 29,049.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.4 | 5.8 | |
| 12,129.0 | 15,918.8 | 1,575.1 | 179.1 | 14.9 | 11.4 | 88.9 | 9.6 | |
| 1,851.1 | 3,162.1 | 673.7 | 202.6 | 17.6 | 19.4 | 15.6 | 5.5 | |
| 603.0 | 7,003.9 | 502.0 | 138.7 | -- | 32.8 | 50.5 | 8.1 | |
| 136.0 | 3,636.7 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.5 |
Senores Pharmaceuticals IPO analysis
5 min read•By Satyajit Sen
--
Incorporated
2017
Chairman
Sanjay Shaileshbhai Majmudar
Managing Director
Swapnil Jatinbhai Shah
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Senores Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Senores Pharmaceuticals Ltd is ₹765.05 (NSE) and ₹764.95 (BSE) as of 19-Mar-2026 10:49 IST. Senores Pharmaceuticals Ltd has given a return of 23.09% in the last 1 years.
The P/E ratio of Senores Pharmaceuticals Ltd is 33.91 times as on 18-Mar-2026, a 2 premium to its peers’ median range of 33.39 times.
The P/B ratio of Senores Pharmaceuticals Ltd is 4.06 times as on 18-Mar-2026, a 88 premium to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
45.04
|
3.35
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2025
|
45.04
|
3.35
|
The 52-week high and low of Senores Pharmaceuticals Ltd are Rs 876.50 and Rs 440.30 as of 19-Mar-2026.
Senores Pharmaceuticals Ltd has a market capitalisation of ₹ 3,445 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Senores Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹15.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.